ASH 2011 - San Diego - CML - Chronic Myeloid Leukemia
2011 ASH Annual Meeting and Exposition - December 10-13, 2011
CML Program
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy
Includes basic studies of any aspect of CML, including pre-clinical and animal models of drug therapy, biological agents, immunotherapy and vaccine development as well as pathophysiology at cellular or molecular levels.
632. Chronic Myeloid Leukemia: Therapy
Includes diagnosis, prognosis, therapy, epidemiology, complications, follow-up, quality of life, and socioeconomic aspects. For comparative trials of treatment regimens versus transplantation, see category 731.
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy
Includes basic studies of any aspect of CML, including pre-clinical and animal models of drug therapy, biological agents, immunotherapy and vaccine development as well as pathophysiology at cellular or molecular levels.
632. Chronic Myeloid Leukemia: Therapy
Includes diagnosis, prognosis, therapy, epidemiology, complications, follow-up, quality of life, and socioeconomic aspects. For comparative trials of treatment regimens versus transplantation, see category 731.
ASH2011 NEWS
ASH: Bone Marrow Best for Unrelated Donor SCT
HyperCVAD Plus Dasatinib Effective in Patients with Ph+ ALL or CML-LB
Onyx Trips, Ariad and Pharmacyclics Shine at Blood Cancer Meeting
BELA Trial: Bosutinib May Be Superior to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
More news for ASH meeting
Nilotinib shows promise as first-line therapy in CML
BELA Trial: Bosutinib bested imatinib in patients with chronic CML (featuring Dr. Cortes)
ENEST: Patients with Ph+CML exhibited deeper responses to nilotinib than imatinib mesylate
CML updatde from 2011 ASH annual meeting
5 Winners Of American Society Of Hematology 2011
Promising treatments for blood cancers presented by JTCancerCenter researchers at ASH meeting
Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease
ASH: Bone Marrow Best for Unrelated Donor SCT
HyperCVAD Plus Dasatinib Effective in Patients with Ph+ ALL or CML-LB
Onyx Trips, Ariad and Pharmacyclics Shine at Blood Cancer Meeting
BELA Trial: Bosutinib May Be Superior to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
More news for ASH meeting
Nilotinib shows promise as first-line therapy in CML
BELA Trial: Bosutinib bested imatinib in patients with chronic CML (featuring Dr. Cortes)
ENEST: Patients with Ph+CML exhibited deeper responses to nilotinib than imatinib mesylate
CML updatde from 2011 ASH annual meeting
5 Winners Of American Society Of Hematology 2011
Promising treatments for blood cancers presented by JTCancerCenter researchers at ASH meeting
Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease
Reporting Live from ASH 2011 by the CML Society of Canada
ASH 2011: Summary of Education Session on CML by CML Advocates Network
ASH 2011 Report: Key news on CML from a patients' perspective by CML Advocates Network
ASH NEWS DAILY – Ernest Beutler Lectures Work Toward CML Cure with Dr. Janet Rowley and Dr. Brian Druker
ASH 2011: Summary of Education Session on CML by CML Advocates Network
ASH 2011 Report: Key news on CML from a patients' perspective by CML Advocates Network
ASH NEWS DAILY – Ernest Beutler Lectures Work Toward CML Cure with Dr. Janet Rowley and Dr. Brian Druker
December 12, 2011 1:30 PM-2:30 PM
San Diego Convention Center (Hall AB)
"Chronic myeloid leukemia (CML) was virtually uniformly fatal before the late 1990s with a median survival of about three years. In 1960, a unique small marker chromosome called the Philadelphia (Ph1) chromosome was identified. In 1973, it was determined to be a translocation that led to a fusion of the involved genes on chromosomes 9 and 22; the gene on 9 was the Abelson (ABL) oncogene, a known tyrosine kinase. This knowledge led to the development of an inhibitor of the ABL tyrosine kinase that specifically killed cultured CML cells. Clinical trials confirmed these pre-clinical observations and this oral drug, imatinib (Gleevec or STI571), has revolutionized treatment with five-year survival rates of almost 90 percent. Thus, although it took 40 years, CML is a story of success, from the identification of a unique genetic change to the development of a remarkably effective genetically targeted therapy. Dr. Janet Rowley will discuss the discovery of the chromosome translocations and cloning of the translocation breakpoint. Dr. Brian Druker will discuss the pre-clinical and clinical development of ABL inhibitors, including the problem of resistance."
Chair(s):
Janet D. Rowley, MD Brian J. Druker, MD
Univ. of Chicago Med. Ctr. OHSU Knight Cancer Institute
Chicago, IL, USA Portland, OR, USA
ASH NEWS DAILY – Ernest Beutler Lectures Work Toward CML Cure with Dr. Janet Rowley and Dr. Brian